AntibodySystem는 Primary Antibody Biosimilar - Research Grade 

제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다. 

제품 설명 

Anti-Eculizumab ELISA Kit

제품 번호

KAB90001

제품 특징

Catalog No.

KAB90001

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

156.25 - 10,000 ng/mL

Precision

CV<20%

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Alternative Names

5G1.1,h5G1.1HuG2/G4,CAS: 219685-50-4

References

Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies., PMID:40515823

Effectiveness and safety of ravulizumab for Japanese patients with atypical hemolytic uremic syndrome switched from eculizumab: an analysis of a post-marketing surveillance., PMID:40515788

DAGLA autoantibody experience at Mayo Clinic., PMID:40512252

Complement inhibition rapidly blocks lesion extension and facilitates remyelination in neuromyelitis optica., PMID:40506785

Emerging Role of Targeted Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders., PMID:40506618

Emergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how., PMID:40505554

[A case of paroxysmal nocturnal hemoglobinuria treated with eculizumab in unintended pregnancy]., PMID:40484825

[Diagnosis, treatment, and genetic analysis of five cases of primary atypical hemolytic uremic syndrome]., PMID:40484823

An updated, comprehensive meta-analysis of the treatment of anti-NMDAR encephalitis: Analysis, equipoise, and the urgent need for evidence over anecdote., PMID:40472799

Complement inhibitor therapy as a steroid-sparing strategy in generalized myasthenia gravis., PMID:40453104

From checkboxes to emojis: a novel approach to patient-reported outcomes in multiple sclerosis., PMID:40447786

Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors., PMID:40447351

Case Report: Hematopoietic Stem Cell Transplantation to Treat Severe Acquired Aplastic Anemia in a Pediatric Kidney Transplant Recipient., PMID:40445946

Advances in Research on the Release of von Willebrand Factor from Endothelial Cells through the Membrane Attack Complex C5b-9 in Sepsis., PMID:40438181

Atypical Haemolytic Uraemic Syndrome., PMID:40436118

Hypertensive Emergency and Atypical Hemolytic Uremic Syndrome Associated with Cocaine Use: A Diagnostic and Therapeutic Challenge., PMID:40422585

The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis., PMID:40422242

Perioperative Management of Atypical Hemolytic Uremic Syndrome in a Patient on Maintenance Eculizumab Therapy: A Case Report and Review of the Literature., PMID:40414204

Validation for soluble C5b-9 detection and comparative analysis of three quantification methods., PMID:40412754

Translating biomarker insights into practice: a path forward in TA-TMA management., PMID:40406401

Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Long-term Follow-up and Therapeutic Challenges in a Treatment-Resistant Case., PMID:40398846

Therapeutics controversies in antineutrophilic cytoplasmic antibody-associated vasculitis., PMID:40392453

Atypical hemolytic uremic syndrome: a rare complication of postendoscopic retrograde cholangiopancreatography pancreatitis., PMID:40386314

Kidney transplant in patients with C3 glomerulopathy., PMID:40385590

PLASMIC score to aid diagnosis of aHUS: an analysis of C5 inhibitor clinical trials and the PINC AI™ healthcare database., PMID:40375186

Incidence of infection associated with eculizumab: a meta-analysis of 9 randomized controlled trials., PMID:40356951

Advancements in Complement Inhibition for PNH and Primary Complement Mediated Thrombotic Microangiopathy., PMID:40354320

Comparative efficacy and acceptability of novel biologics in the treatment of myasthenia gravis: systematic review and network meta-analysis of randomized trials., PMID:40346603

Eculizumab in severe pediatric STEC-HUS and its impact on neurological prognosis-a systematic review and meta-analysis., PMID:40341411

Drug-Induced Thrombotic Microangiopathy Arising During the Treatment of Anal Carcinoma After the Use of Mitomycin C., PMID:40330382

Rapid response of eculizumab: a rescue therapy for ventilator-dependent refractory myasthenic crisis., PMID:40327031

Interferon Causes Endothelial Injury in Humans., PMID:40326264

Clinical Features and Factors Associated With Outcome in Late Adult-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease., PMID:40324120

Utility of spinal cord axial-T2 sequence in a population-based cohort of multiple sclerosis., PMID:40301133

Complement dysregulation at lymphatics., PMID:40300720

Correction: A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients., PMID:40299078

Eculizumab as fast-acting rescue therapy for pembrolizumab-induced impending crisis state of myasthenia gravis: a case report., PMID:40297820

Eculizumab as Treatment in Refractory Impeding and Myasthenic Crisis: A Case Series., PMID:40295418

Assessing fall risk in multiple sclerosis using patient-reported outcomes and wearable gait metrics., PMID:40292035

Anchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria., PMID:40285403

Complement in Antibody-Mediated Rejection of the Kidney Graft: From Pathophysiology to Clinical Practice., PMID:40283639

Dose Adjustments of Pegcetacoplan in a Patient With Paroxysmal Nocturnal Hemoglobinuria Undergoing Surgery: A Case Report., PMID:40276419

Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment., PMID:40273330

Neuromyelitis optica spectrum disorder in Latin America: a global data share initiative., PMID:40267692

Treatment of atypical hemolytic uremic syndrome with eculizumab in a patient presenting with neuropsychiatric prodrome: a case report., PMID:40264782

Late Relapse After Autologous Hematopoietic Stem Cell Transplantation in AQP4-IgG-Positive NMOSD., PMID:40257801

The Advancing Landscape of Paroxysmal Nocturnal Hemoglobinuria Treatment., PMID:40257298

Eculizumab is efficacious and safe in pediatric patients with various forms of hemolytic uremic syndrome: a retrospective clinical experience of a tertiary center., PMID:40255570

Paroxysmal nocturnal haemoglobinuria in pregnancy-a systematic review with meta analysis., PMID:40244439

Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension., PMID:40241307

AntibodySystem의 모든 제품들을 만나 보세요!  

Products

Recombinant Protein

Antibody

Assay Kit

Research Biosimilar

Enzyme

Trending Product

Super-Affinity Antibody

Cell Lysates

Antibodysystem - Official Distributor in South Korea "Morebio" 한국 독점 대리점 "모아바이오"